← Back to All Filings

Johnson & Johnson Sells Minor CVRx Stake Valued at $10K

Low SignificanceNovember 14, 2025 at 3:34:55 PM EST

CVRx, Inc.

$CVRX4CIK: 0001235912

Subscribe to track CVRX

Premium users can add ticker alerts and receive realtime notification updates.

Filing Summary

Johnson & Johnson Sells Minor CVRx Stake Valued at $10K

Company: CVRx, Inc. (CVRX) Form: 4 | Filed: 2025-11-14 Significance: Low

Insider: JOHNSON & JOHNSON Relationship: 10% Owner

Transaction: • Type: Sale • Shares: 1,000 • Price: ~$10.00 • Value: $10,000 • Owned After: 4,049,898

Key Insight: A very small sale by a major institutional holder (Johnson & Johnson), representing a negligible fraction (~0.025%) of its total position in CVRx.

Market Context: The transaction is immaterial in value and size, suggesting it is not a strategic shift in J&J's investment thesis for CVRx. The provided market data for J&J is not relevant to the issuer, CVRx.

View Full Filing

This is PUBLIC SEC data for educational purposes. Not investment advice.

Comprehensive Analysis

SEC Filing Analysis: CVRx, Inc. (CVRX)

Executive Summary

  • Trading Significance: Low
  • Key Takeaway: Johnson & Johnson, a greater than 10% owner, executed a nominal $10,000 sale of CVRx stock, representing a minuscule fraction of its total holdings.
  • Market Impact: Neutral. The transaction is too small to be considered market-moving.

Company Information

FieldValue
CompanyCVRx, Inc.
Ticker SymbolCVRX
CIK0001235912
IndustrySURGICAL & MEDICAL INSTRUMENTS & APPARATUS

Insider Information

FieldValue
NameJOHNSON & JOHNSON
CIK0000200406
Title/Positionnull
Relationship10% Owner

Transaction Details

FieldValue
Form Type4
Transaction Date2025-11-12
Transaction CodeS (Sale)
Security TypeCommon Stock
Shares Involved1,000
Price Per Share$10.00 (Weighted Average)
Total Value$10,000
Shares Owned After4,049,898
Ownership TypeIndirect (By Johnson & Johnson Innovation - JJDC, Inc.)

Financial Impact Assessment

Transaction Materiality

Note: Market data for the issuer (CVRx, Inc.) was not provided. The provided market data for the filer (Johnson & Johnson) is not applicable for this analysis. Therefore, materiality as a percentage of market cap and shares outstanding for CVRx cannot be calculated.

  • Transaction Value: $10,000
  • Shares Sold vs. Holdings: The 1,000 shares sold represent approximately 0.025% of Johnson & Johnson's prior holdings in CVRx.
  • Materiality Assessment: Low. Based on the absolute transaction value and its negligible size relative to the insider's total position, the sale is immaterial.

Impact Evaluation

  • Ownership Concentration: Johnson & Johnson remains a significant shareholder with over 4 million shares held indirectly through its subsidiary, JJDC, Inc.
  • Transaction Significance: This is a routine, non-strategic transaction. Its small size indicates it is likely for administrative purposes, portfolio rebalancing, or liquidity and does not signal a change in J&J's conviction in CVRx.

Market Impact Analysis

Stock Impact Prediction

  • Direction: Neutral
  • Reasoning: The sale of $10,000 worth of stock is insignificant and will not influence market perception or the stock's price.

Volume & Sentiment

  • Expected Volume Impact: None. The transaction is too small to affect trading volume.
  • Sentiment Indicator: Neutral. The filing does not provide any bullish or bearish signals.

Additional Context

Transaction Notes

  • Footnote 1: The reported price of $10.00 is a weighted average price from multiple trades.
  • Footnote 2: The shares are held directly by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of Johnson & Johnson.
Topics:#SECFiling#InsiderTrading#CVRX#CVRXStock#JNJ#Form4#InsiderSell#StockMarket#Investing#MarketAnalysis

Get Real-Time Alerts

Join our community to receive instant notifications when high-significance filings are published

Important Disclaimer

This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.

Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.